Stem cells used in AIDS fight; genetic mutation guarantees heart problems;

Stem Cell Research

Scientists are blazing a new trail to fight AIDS, inserting HIV-resistant genes into stem cells and inserting them into patients' bone marrow. And in a small human trial, some of the stem cells were able to produce HIV-resistant stem cells that helped improve their condition. Report

President Barack Obama says that he wants new legislation allowing wider federal support for stem cell research, though he adds that he is still considering achieving the same objective through an executive order. Story

A new study suggests that adult bone marrow stem cells can be used in the construction of artificial skin. The findings mark an advancement in wound healing and may be used to pioneer a method of organ reconstruction. Release

Australia's Mesoblast Limited says it has received Australian institutional ethics approval to begin the first human trial of adult stem cell treatment for prevention of knee osteoarthritis after an acute traumatic knee injury. Release

Genetics

A new study says that three newly identified genetic variations could be responsible for up to half of all cases of severe obesity. Report

There's a growing debate whether the genetic similarities between schizophrenia and bipolar disease mean that both ailments are a continuum of the same disease. Story

Researchers say they have identified a genetic mutation that all but guarantees a person will develop heart problems--and four percent of South Asians have it. Report

Cancer Research

InNexus Biotechnology reports that a primate study has underscored the safety and efficacy of its experimental therapy for non-Hodgkins lymphoma tumors. Report

deCODE genetics, an Iceland-based biopharmaceutical company, has launched new genetic scans for assessing personal risk of several major cardiovascular diseases and common cancers through deCODEme. Report

Suggested Articles

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Selectively targeting TGF-beta1 with Scholar Rock's SRK-181 overcame primary resistance to checkpoint inhibitor therapy in mice.

Enhertu produced a 55.6% objective response rate in HER2-positive non-small cell lung cancer patients in a phase 1 trial.